Skip to main content
OpenTrials
Completed

NCT Number: NCT03533010

Preventing Curve Progression and the Need for Bracing in Adolescent Idiopathic Scoliosis With Calcium + Vitamin D Supplementation

There is an association between adolescent idiopathic scoliosis (AIS) and low bone mass which has been reported to be a significant prognostic factor for curve progression. Given that dietary calcium (Ca) intake and serum Vit-D levels were also low in AIS, we therefore propose a randomized double-blinded placebo-controlled trial to evaluate if daily [500mg Ca + 800 IU Vit-D] can improve bone health and prevent curve progression in AIS. Immature AIS girls with Cobb angle 10-20 degrees will be randomized either to the Treatment or Placebo group with 3-year of treatment. The main outcome measures for evaluation for those who have completed the 3-year treatment and have reached skeletal maturity at the end of 3-year treatment include: (1) percentage of patients with increase in Cobb angle≥6 degrees and (2) percentage of patients who require bracing. Bone measurements using advanced image acquisition technology(HR-pQCT) to assess bone health will also be evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Age range

10 year–14 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Department of Orthopaedics and Traumatology, Prince of Wales Hospital

Hong Kong

About this study

This study investigates if calcium (Ca) plus Vitamin D (Vit-D) supplementation can prevent curve progression and improve bone health in early Adolescent Idiopathic Scoliosis (AIS) during pubertal growth.

AIS is a prevalent three-dimensional spinal deformity mainly affecting girls at puberty. It can lead to serious complications including spine degeneration, cardiopulmonary compromise, grossly deformed torso and psychosocial disorders. Current treatments are far from being satisfactory, with bracing being lengthy and physically demanding and surgery being a major invasive procedure.

There is an association between AIS and low bone mass which has been reported to be a significant prognostic factor for curve progression. Given that dietary calcium intake and serum Vit-D levels were also low in AIS, we therefore propose a randomized double-blinded placebo-controlled trial to evaluate if daily [500mg Ca + 800 IU Vit-D] can improve bone health and prevent curve progression. Immature AIS girls with Cobb angle 10-20 degrees will be randomized either to the Treatment or Placebo group with 3-year of treatment. The main outcome measures for evaluation for those who have completed the 3-year treatment and have reached skeletal maturity at the end of 3-year treatment include: (1) percentage of patients with increase in Cobb angle≥6 degrees and (2) percentage of patients who require bracing. Bone measurements using advanced image acquisition technology (HR-pQCT) to assess bone health will also be evaluated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • girls with diagnosis of AIS confirmed after detailed clinical and radiological assessment and
  • between 10 to 14 years old and
  • Risser between 0 to 2 and
  • pre-menarche or < 1 year post-menarche and
  • Cobb angle between 10° to 20 ° and
  • no prior bracing or other treatment for scoliosis and
  • no prior treatment for bone health

Exclusion criteria

  • scoliosis with any known etiology such as congenital scoliosis, neuromuscular scoliosis, scoliosis of metabolic etiology, scoliosis with skeletal dysplasia or
  • patients with known endocrine and connective tissue abnormalities, or
  • patients with eating disorders or gastrointestinal malabsorption disorders or any disorders that are known to affect calcium or bone metabolism or
  • prior treatment for bone health before being recruited into the study or
  • patient currently taking medication that affects bone metabolism eg steroid or
  • patient with contra-indications for calcium and Vit-D supplementation:
  • history of hypersensitivity to the active or placebo tablets
  • history of renal diseases and renal calculi (nephrolithiasis)
  • diseases and/or conditions resulting in hypercalcaemia and/or hypercalciuria
  • hypervitaminosis D

Treatment and study plan

Ca500mg

Dietary Supplement

subjects receive a daily dose of 500mg elemental calcium

Other names: Calcium 500mg

VitD800IU

Dietary Supplement

subjects receive a daily dose of 800IU VitD3

Other names: Vitamin D3 800IU

Placebo

Other

subjects receive placebo tablet

Primary outcomes

  1. Curve progression (Cobb)

    Time frame: 3 years

    Percentage of patients with increase in Cobb angle ≥ 6 degrees

  2. Curve progression (Bracing)

    Time frame: 3 years

    Percentage of patients who require bracing

Secondary outcomes

  1. Bone health (BMD)

    Time frame: 3 years

    Improvement in areal bone mineral density measured with Dual-energy X-ray absorptiometry

  2. Bone health (bone quality)

    Time frame: 3 years

    Improvement in bone quality measured with High-resolution peripheral quantitative computed tomography

Sponsors and collaborators

Lead sponsor

Chinese University of Hong Kong

Other

Registry information

Official study title

Preventing Curve Progression and the Need for Bracing in Early Diagnosed Adolescent Idiopathic Scoliosis Using Calcium Plus Vitamin D Supplementation - A Randomized Double-blinded Placebo-controlled Trial

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
May 22, 2018
Registry last updated
Dec 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.